Results 71 to 80 of about 74,688 (254)
SnoRNA U50A mediates everolimus resistance in breast cancer through mTOR downregulation
Translational OncologyBreast cancer remains the most prevalent cancer in women globally, posing significant challenges in treatment due to the inevitable development of resistance to targeted therapies like everolimus, an mTOR inhibitor. While several mechanisms of resistance
Jie-Ning Li +5 more
doaj +1 more source
Cost Effectiveness and Resource Allocation, 2023 Objective Renal cell carcinoma (RCC) is the most common type of kidney cancer. VEGF inhibitors and mTORs are the most common therapeutic options among the different classes of available treatments.
Zahra Goudarzi +7 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Limited evidence exists synthesizing the risk of acute kidney injury (AKI) associated with the concomitant administration of multiple nephrotoxic drugs, and even less examining the concept of nephrotoxic burden. The objective of this scoping review was to (1) identify definitions of nephrotoxic burden; (2) methods used to quantify (use of calculations)
Wafa Alatawi +6 more
wiley +1 more source
Safety and Efficacy of Everolimus in Adult Patients with Neuroendocrine Tumors
Clinical Medicine Insights: Oncology, 2012 Neuroendocrine tumors (NETs) consist of a diverse family of tumors which are derived from the neuroendocrine system. Most NETs are well or moderately differentiated tumors with a relatively indolent growth pattern.
Paul E. Oberstein, M. Wasif Saif
doaj +1 more source
Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms
Endocrine Connections, 2019 Comparisons between everolimus and sunitinib regarding their efficacy and safety in neuroendocrine neoplasms (NENs) are scarce. We retrospectively analysed the clinicopathological characteristics and outcomes in 92 patients with well-differentiated (WD ...
Kosmas Daskalakis +7 more
doaj +1 more source
Inhibition of chondrosarcoma growth by mTOR inhibitor in an in vivo syngeneic rat model. [PDF]
PLoS ONE, 2012 BACKGROUND: Chondrosarcomas are the second most frequent primary malignant type of bone tumor. No effective systemic treatment has been identified in advanced or adjuvant phases for chondrosarcoma.
Jennifer Perez +7 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Cannabidiol (CBD) is one of the most abundant bioactive cannabinoids. Research has demonstrated CBD’s ability to inhibit metabolic enzymes like cytochrome P450 (CYP) and UDP‐glucuronosyltransferase (UGT), potentially leading to drug interactions. However, clinical knowledge gaps remain, particularly with regard to drugs that are more commonly taken by ...
Pablo Salcedo +11 more
wiley +1 more source
Experimental Hematology & Oncology, 2018 Background We evaluated the cost-effectiveness of nivolumab versus everolimus in patients with advanced renal cell carcinoma (RCC) from a US payer perspective.
Charles McCrea +3 more
doaj +1 more source
Cellular antiseizure mechanisms of everolimus in pediatric tuberous sclerosis complex, cortical dysplasia, and non-mTOR-mediated etiologies. [PDF]
, 2018 The present study was designed to examine the potential cellular antiseizure mechanisms of everolimus, a mechanistic target of rapamycin (mTOR) pathway blocker, in pediatric epilepsy cases. Cortical tissue samples obtained from pediatric patients (n
Barry, Joshua +8 more
core +2 more sources
Epilepsia, EarlyView.Abstract Objective In epilepsy, daily treatment provides only symptomatic seizure control, leaving a significant unmet need for a treatment that affects the underlying predisposition to seizures. Here, in a first‐of‐its‐kind study, we test the hypothesis that intermittent treatment of seizure clusters with diazepam in the kainic acid post‐status ...
Qian Wu +8 more
wiley +1 more source